quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:00·668d
PRRelease
Contineum Therapeutics Inc. logo
Ionis Pharmaceuticals Inc. logo
Novartis AG logo
+3

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

CTNM· Contineum Therapeutics Inc.IONS· Ionis Pharmaceuticals Inc.NVS· Novartis AGRNA· Atrium Therapeutics Inc.AKCA· Akcea Therapeutics, Inc.BLI· Berkeley Lights Inc.
Health Care
Original source

Companies

  • CTNM
    Contineum Therapeutics Inc.
    Health Care
  • IONS
    Ionis Pharmaceuticals Inc.
    Health Care
  • NVS
    Novartis AG
    Health Care
  • RNA
    Atrium Therapeutics Inc.
    Health Care
  • AKCA
    Akcea Therapeutics, Inc.
    Health Care
  • BLI
    Berkeley Lights Inc.
    Health Care

Recent analyst ratings

  • Apr 21IONSUpdateCanaccord Genuity$110.00
  • Apr 10IONSUpdateRaymond James$104.00
  • Mar 11RNAUpdateWells Fargo$25.00
  • Mar 11NVSUpdateArgus$180.00
  • Jan 28IONSUpdateBarclays$95.00
  • Jan 27NVSUpdateCitigroup-

Related

  • SEC9h
    SEC Form DEFA14A filed by Ionis Pharmaceuticals Inc.
  • SEC9h
    SEC Form DEF 14A filed by Ionis Pharmaceuticals Inc.
  • PR18h
    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
  • INSIDER1d
    SEC Form 4 filed by Kenney Stephanie
  • INSIDER1d
    SEC Form 4 filed by Hughes Steven George
  • INSIDER1d
    SEC Form 4 filed by Winslow Brendan R.
  • INSIDER1d
    SEC Form 4 filed by Gallagher Kathleen P.
  • INSIDER1d
    SEC Form 4 filed by Hoyos Rocio Martin
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022